The Genomic Landscape of Plasma Cells in Systemic Light chain Amyloidosis

Authors: Eileen M. Boyle1,2,3, Cody Ashby1, Christopher P. Wardell1, Dorota Rowczenio4, Sajitha Sachchithanantham4, Yan Wang1, Sarah K. Johnson1, Michael A. Bauer1, Niels Weinhold1, Martin F. Kaiser5, David C. Johnson5, John R. Jones5, Charlotte Pawlyn5, Paula Proszek5, Carolina Schinke1, Thierry Facon2, Charles Dumontet3, Faith E. Davies1, Gareth J. Morgan1, Brian A. Walker1*, and Ashutosh D. Wechalekar4*

1 Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
2 Service des maladies du sang. Hôpital Claude Huriez, Lille University Hospital, Lille, FRANCE.
3 INSERM 1052/CNRS 5286 Cancer Research Center of Lyon, Lyon, FRANCE
4 National Amyloidosis Centre, University College London, London, UK
5 The Institute of Cancer Research, London, UK
*These authors contributed equally

Corresponding Author: Ashutosh D. Wechalekar
Address: National Amyloidosis Centre, University College London (Royal Free Campus), Rowland Hill Street, London NW3 2PF, UK
Email: a.wechalekar@ucl.ac.uk
Tel: +44 (0)20 7433 2802
Fax: +44 (0)20 7433 2817

Running title: Landscape of AL mutations
Words: 1193 (1200)
Figures and tables: 1+1 (2)
References: 18 (25)
Category: Letter
TO THE EDITOR:
The key event in the pathogenesis of Systemic light chain amyloidosis (AL) is an unstable misfolded secondary or tertiary structure of a monoclonal immunoglobulin (IG) light chain, that precipitates in the extracellular compartments. The plasma-cell disorder underlying AL, is likely to lie within the common spectrum of plasma-cell diseases, but limited confirmatory data analysing the genetic architecture of AL are available.

To address this, we prospectively included twenty-four newly diagnosed histologically proven AL samples from the National Amyloid Centre, University College London, UK, prior to any treatment. AL was confirmed by immunohistochemistry or mass spectrometry. CD138+ cells and peripheral blood were isolated, DNA extracted and used in an exome capture protocol and sequenced as previously published. This AL dataset was compared to previously published MGUS and MM datasets and filtered similarly to ensure comparability of mutation numbers. Detailed methods and Patient’s characteristics may be found in the Supplemental-Methods and Supplemental-Table 1.

In terms of mutational burden, the median number of exonic, non-IG, non-synonymous mutations per sample that had a tumour variant allelic fraction greater than 5% was 39 (interquartile range (IQR): 5-185) which is more than was seen in MGUS (20 (IQR: 1-41), p=0.002) but not statistically different from MM (35 (IQR: 3-74), p=0.4), Figure 1A. When analysing the individual genes, we identified a total of 1491 genes that were mutated in our dataset with 236 of them being mutated more than once. As expected, there was no unifying mutation in AL. The dataset was too small to identify any significantly mutated genes. Among the recurrently mutated genes (Supplemental-Table 2), mutations in IL7R, a gene that encodes for a cell surface receptor known to regulate V(D)J recombination by altering the accessibility of DNA substrates to the recombinase in pro-B-cells, were noted. Thirty-seven percent of samples (n=9) had a mutation in one of the 63 previously described MM-driver genes. This is less than MM (84.1%) and similar to MGUS (36%). The number of mutated driver-genes per sample ranged from zero to five. Among the 63 driver-genes, 13 were mutated, Table 1. Most of these mutations were sub-clonal with IG-adjusted estimated tumour fractions ranging from 18% to 100% (Supplemental-Table 3). We identified cases with MM hotspot mutations in NRAS (Q61R and Q61H) but not in KRAS. Even though a trend for fewer KRAS mutations in AL was observed, there was no significant difference in the incidence of driver mutations between MM, MGUS, and AL, Figure 1B. Interestingly there were mutations in some of the other driver-genes such as EGR1 (Q95R), DIS3 (D479E, Q480H).
M667L), IRF4 (S332G), and TRAF3 (K99_sp). Only the same TRAF3 (K99_sp) and DIS3 (D479E, M667L) mutations were seen in the MM dataset. Supplemental-Figure 1A-E.9 In MM, IRF4 mutations are associated with t(11;14), and in this AL dataset the IRF4 mutation (S332G) occurred in a non t(11;14) patient and was neither at the K123R hotspot seen in MM6 nor the L116R seen in CLL.10 There were no mutations in the previously reported adverse prognostic genes such as ATM, ATR, ZFHX4 and TP53, nevertheless mutations in BRCA2 (P1088T, N372H) and the driver-gene EP300 (I997V) were seen suggesting DNA-repair pathway involvement. Copy-number analysis did not reveal any copy number changes at these loci suggesting the absence of bi-allelic inactivation. Finally, evidence would suggest the presence of NF-κB pathway activation, with not only mutations in the driver-genes (such as TRAF3, IRF4) but also mutations in kinases (such as LYN (I165T)), downstream transducing molecules (CARD11 (R1077V)) and inhibitors (NFKBIE_sp), Supplemental-Figure 2. We compared the mutational landscape of AL to previously sequenced MM (n=1273)9 and MGUS (n=33)4 samples. Overall, there were 101 genes in common between AL, MGUS, and MM. Ninety-three percent of the AL-mutated genes (n=1386) were shared with either MM or MGUS. Only 7% of these genes (n=105) had not previously been reported in MM or MGUS, Supplemental-Figure 3 and Table 4. None of these mutations were recurrent. A Gene enrichment analysis of the 105 genes that were mutated in AL only11 did not reveal any specific pathway enrichment suggesting they are random. There were no mutations in the ribosome sub-unit genes.12 Among the 68 differentially expressed genes (Paiva et al.), we only identified a mutation in TIAM2 previously reported in MM.2 Of note, we did identify a mutation in the 8th exon of PSMA2 gene (P223S) that was among the differentially expressed genes found by Abraham et al13. In a hierarchical clustering approach of driver mutation based on previously published data,4,5,14,15 AL clustered with MGUS and was closely related to MM, Figure 1C. In terms of translocations, we identified seven t(11;14) encompassing 30% of cases. The breakpoints, located 2-600 kb upstream of CCND1, were consistent with those seen in other lymphoid malignancies, Supplemental-Figure 4. They were all generated via class switch recombination with breakpoints occurring in the IGHA1 (2/7) and IGHM (5/7) switch regions. There was no evidence of other canonical translocation but we identified a t(1;14) involving IGHG4 and the RCC1 gene in a t(11;14) patient, Supplemental-Figure 5. There was no evidence of inter-chromosomal translocations involving MYC; one patient had an 8q24 gain, 5’ to MIR1208, suggesting MYC rearrangements also occur in AL. Regarding other cytogenetic abnormalities, there was no difference in the incidence of copy number changes with the exception of del(1p), and
del(14q) that was lower than expected in MM (n=1, 4%, p=0.008 and n=0, p<0.0001 respectively) but similar to MGUS, Supplemental-Figure 6.

This is the largest dataset of whole exome sequencing (WES) of AL to date and combined, these data suggest the underlying disease in AL resembles other plasma-cell disorders such as MGUS and MM. The number of mutations in AL was comparable to MM suggesting AL is a more complex disease than MGUS. Like previously published AL cases that had undergone WES, we failed to identify any unifying mutation. We were nonetheless able to detect MM-defined driver mutations. They occurred at similar frequencies to MGUS and were less common than in MM. They were predominantly sub-clonal suggesting they occurred late during disease progression. There was evidence of mitogen activated protein kinase (MAPK) activation with NRAS mutations (8%) in keeping with previously published data by Rossi et al16, NF-κB activation (17%) and DNA-repair pathway alterations (12%). Unlike previous reports, none of the NRAS mutated patients had classical CRAB criteria but one had another myeloma defining event (SFLC ratio>100 with an involved chain greater than 1000 mg/L).17 These data are consistent with observations from MGUS and SMM where NRAS mutations may be found with lower frequencies than in MM.4,16,18 There was a 93% overlap in mutated genes indicating a common spectrum of mutations between AL and other plasma-cell disorders. Attempts to cluster patients based on MM-driver genes placed AL close to MM and MGUS and not with other lymphoid malignancies.

Overall AL showed a similar mutation burden to MM but resembled MGUS in terms of copy number changes and driver-gene mutations suggesting AL lies within the continuous spectrum from MGUS to MM. Given that the similarities with MGUS and MM are outweighing the differences, it is unlikely that the plasmacell biology per se explains the clinical presentation of AL, however, these data support the ongoing use of myeloma-based therapy for this disease.
Acknowledgements
We acknowledge The Institute of Cancer Research Tumour Profiling Unit for their support. This work was supported by a Myeloma UK program grant, a Cancer Research UK CTAAC sample collection grant and a Cancer Research UK Biomarkers and Imaging Discovery and Development grant as well as funds from the National Institute of Health Biomedical Research Centre at the Royal Marsden Hospital. EMB was supported by a grant from the Fédération française de recherche sur le myélome et les gammapathies under the auspices of La Fondation de France.

Authorship contributions
Conception and design of the study: EMB, DR, BAW, GJM, ADW

Acquisition of data: EMB, DR, BAW, SS, ADW, PP

Analysis of data: EMB, CA, YW, CPW, MAB, NW, BAW, MFK, DCJ, JRJ, CP, TF, CD, CS, FED, GJM

Writing of manuscript: EMB, BAW, GJM, ADW

Review or revision of manuscript: all.

Conflicts of Interest
The authors have no relevant conflicts of interest to disclose.
References

### Table 1: Driver mutations found in AL

<table>
<thead>
<tr>
<th>Gene</th>
<th>Number of mutations</th>
<th>Number of patients</th>
<th>Variants</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIS3</td>
<td>2</td>
<td>1</td>
<td>D479E, M667L</td>
</tr>
<tr>
<td>DUSP2</td>
<td>1</td>
<td>1</td>
<td>Splice donor variant</td>
</tr>
<tr>
<td>EGR1</td>
<td>1</td>
<td>1</td>
<td>Q95R</td>
</tr>
<tr>
<td>EP300</td>
<td>1</td>
<td>1</td>
<td>I997V</td>
</tr>
<tr>
<td>IRF4</td>
<td>1</td>
<td>1</td>
<td>S332G</td>
</tr>
<tr>
<td>KLHL6</td>
<td>1</td>
<td>1</td>
<td>V337M</td>
</tr>
<tr>
<td>KMT2B</td>
<td>1</td>
<td>1</td>
<td>P204H</td>
</tr>
<tr>
<td>NRAS</td>
<td>2</td>
<td>2</td>
<td>Q61R; Q61H</td>
</tr>
<tr>
<td>SAMHD1</td>
<td>1</td>
<td>1</td>
<td>F363L</td>
</tr>
<tr>
<td>TET2</td>
<td>1</td>
<td>1</td>
<td>P363L</td>
</tr>
<tr>
<td>TRAF3</td>
<td>1</td>
<td>1</td>
<td>Splice donor variant</td>
</tr>
<tr>
<td>ZFP36LI</td>
<td>1</td>
<td>1</td>
<td>L82S</td>
</tr>
<tr>
<td>ZNF292</td>
<td>1</td>
<td>1</td>
<td>I1740V</td>
</tr>
</tbody>
</table>
Figure Legends

**Figure 1: The mutational spectrum of amyloidosis resembles MM and MGUS.**

A: Boxplot suggesting AL has more mutations than MGUS but not a statistically different number than MM. B: Frequencies of select driver mutations in AL, MGUS and MM. C: Clustering of driver-mutation frequencies
### Figure 1

**A.**

- **Number of mutations**
  - MM (n=463)
  - AL (n=24)
  - MGUS (n=33)
  - P-values: p=0.4, p=0.002

**B.**

- **Proportion**
  - MM
  - AL
  - MGUS

**C.**

- Driver genes:
  - KRAS
  - NRAS
  - DIS3
  - FAM46C
  - BRAF
  - TP53
  - HUWE1
  - TRAF3
  - EGR1
  - DUSP2
  - IRF4
  - ZNF292
  - KLHL6
  - KMT2C
  - CREBBP
  - ATRX
  - KMT2B
  - EP300
  - TET2
  - SAMHD1
  - RASA2
  - ZFP36L1

- Other genes:
  - ATM
  - SF3B1
  - TP53
  - HIST1H1E
  - KLHL6
  - ZFP36L1
  - CREBBP
  - KRAS
  - FAM46C
  - BRAF
  - DIS3
  - NRAS
  - EGR1
  - EP300
  - DUSP2
  - HUWE1
  - ACTG1
  - LTB
  - NFKBIA
  - RFTN1
  - ATRX
  - SETD2
  - CCND1
  - CDKN1B
  - PRKD2
  - SAMHD1
  - KMT2B
  - TET2
  - TRAF3
  - ZNF292
  - IRF4
  - C8ORF34
  - PIK3CA
  - ARID2
  - DNMT3A
  - ABCF1
  - NFKB2
  - RASA2
  - TGDS
  - IDH2
  - MAFB
  - CDKN2C
  - MAF
  - MAN2C1
  - IDH1
  - MAML2
  - NCOR1
  - XBP1
  - FGFR3
  - UBR5
  - CYLD
  - MAX
  - KDM6A
  - KDM5C
  - PRDM1
  - RB1
  - SP140
  - NF1
  - FUBP1
  - KMT2C
  - TRAF2
  - ARID1A
  - PTPN11
The genomic landscape of plasma cells in systemic light chain amyloidosis


Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.